Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma

The relative dose intensity (RDI) at 4 weeks after second-line targeted therapy induction may be a possible predictor of prognosis in patients with metastatic renal cell carcinoma treated with second-line targeted therapy, particularly in the International Metastatic Renal Cell Carcinoma Database Consortium poor-risk group and everolimus-treated subjects. Overall survival of patients with second-line RDI < 0.7 is significantly shorter than those with RDI ≥ 0.7.